Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Lin

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Blood|March 31, 2010
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibitionErin Hertlein, Amy J Wagner, Jeffrey Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin, Kristie A Blum, Diane Beth Fischer, et al.
Blood|April 19, 2007
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalXiaobin Zhao, Rosa Lapalombella, Trupti Joshi, et al.
Blood|September 30, 2006
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay, Susan M Geyer, Timothy G Call, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantationWilliam Blum, Brian J Bolwell, Gary Phillips, et al.
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Future Oncology (London, England)|February 17, 2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
British Journal of Haematology|March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood|October 7, 2004
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaJohn C Byrd, Guido Marcucci, Mark R Parthun, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Blood|March 31, 2010
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibitionErin Hertlein, Amy J Wagner, Jeffrey Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin, Kristie A Blum, Diane Beth Fischer, et al.
Blood|April 19, 2007
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalXiaobin Zhao, Rosa Lapalombella, Trupti Joshi, et al.
Blood|September 30, 2006
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay, Susan M Geyer, Timothy G Call, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantationWilliam Blum, Brian J Bolwell, Gary Phillips, et al.
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Future Oncology (London, England)|February 17, 2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
British Journal of Haematology|March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood|October 7, 2004
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaJohn C Byrd, Guido Marcucci, Mark R Parthun, et al.
Pageof 8